PLYX · Polaryx Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed May 15, 2026
Total shares sold short and not yet covered, reported to FINRA by broker-dealers twice a month. Each reading settles on the 15th and the last business day of the month and is published seven business days later — the next scheduled dates are listed at the top of the table. Days to cover divides the short position by average daily volume; a high value (above 5) can signal short-squeeze potential.
Peer-relative percentile rank across all stocks reporting short interest at the latest settlement date (2026-07-15). Weighted mean of the available factors (short interest 30%, days to cover 20%, price vs VWAP 15%, short-volume trend 15%, short-interest change 10%, fails-to-deliver 10%) plus catalyst boosts (price spike, volume surge, earnings within days), capped at +20 and clamped to 100.
Short Interest History
| Settlement Date | Current Position | Previous Position | Change | Days to Cover |
|---|---|---|---|---|
|
2026-08-14
Scheduled
FINRA publishes Aug 25
|
— | — | — | — |
|
2026-07-31
Scheduled
FINRA publishes Aug 11
|
— | — | — | — |
| 2026-07-15 | 306,529 | 408,516 | -101,987 | 3.04 |
| 2026-06-30 | 408,516 | 441,717 | -33,201 | 3.82 |
| 2026-06-15 | 441,717 | 347,184 | +94,533 | 2.05 |
| 2026-05-29 | 347,184 | 180,109 | +167,075 | 1.00 |
| 2026-05-15 | 180,109 | 266,647 | -86,538 | 1.10 |
| 2026-04-30 | 266,647 | 237,711 | +28,936 | 1.86 |
| 2026-04-15 | 237,711 | 393,306 | -155,595 | 1.26 |
| 2026-03-31 | 393,306 | 434,184 | -40,878 | 1.00 |
| 2026-03-13 | 434,184 | 217,092 | +217,092 | 1.00 |
| 2026-02-27 | 217,092 | 26,175 | +190,917 | 1.00 |
| 2026-02-13 | 26,175 | 0 | +26,175 | 1.00 |